发明名称 MULTIMODAL SILICA-BASED NANOPARTICLES
摘要 The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
申请公布号 US2014248210(A1) 申请公布日期 2014.09.04
申请号 US201414215879 申请日期 2014.03.17
申请人 CORNELL UNIVERSITY ;SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 发明人 Bradbury Michelle;Wiesner Ulrich;Medina Oula Penate;Burns Andrew;Lewis Jason;Larson Steven;Quinn Tom
分类号 A61K51/12;A61K47/48;A61K49/00 主分类号 A61K51/12
代理机构 代理人
主权项 1. A method for detecting tumor cells comprising the steps of: (a) administering to a patient a plurality of fluorescent silica-based nanoparticles in a dose ranging from about 0.01 nanomole/kg body weight to about 1 nanomole/kg body weight, the nanoparticle comprising: A silica-based core comprising a fluorescent compound positioned within the silica-based core;a silica shell surrounding at least a portion of the core;an organic polymer attached to the nanoparticle;a ligand attached to the nanoparticle and capable of binding a tumor marker; andat least one therapeutic agent; and (b) detecting the nanoparticles.
地址 Ithaca NY US